<DOC>
	<DOC>NCT00552929</DOC>
	<brief_summary>The objective of the trial was to establish the dose-response relation of Org 25969 given as a reversal agent of rocuronium or vecuronium at 1-2 PTC during sevoflurane anesthesia for Caucasian subjects</brief_summary>
	<brief_title>A Bridging Trial Comparing Org 25969 at 1-2 PTC in Japanese and Caucasian Subjects. Part B: Caucasian Subjects (19.4.209B)(P05974)</brief_title>
	<detailed_description />
	<mesh_term>Rocuronium</mesh_term>
	<mesh_term>Vecuronium Bromide</mesh_term>
	<criteria>Subjects of ASA class 1 3; Subjects at least 20 years but under 65 years of age; Caucasian subjects; Subjects scheduled for elective surgery requiring muscle relaxation in supine position and under sevoflurane anesthesia with an anticipated duration of about 1.5 3 hours; Subjects who had given written informed consent. Exclusion criteria: Subjects in whom a difficult intubation because of anatomical malformations was expected; Subjects known or suspected to have neuromuscular disorders impairing NMB and/or significant renal dysfunction (for example a creatinine level &gt; 1.6 mg/dl) and/or severe hepatic dysfunction. Subjects known or suspected to have a (family) history of malignant hyperthermia; Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia; Subjects receiving medication expected to interfere with the rocuronium or vecuronium given in this trial, based on the dose and time of administration; Female subjects who were pregnant; Female subjects of childbearing potential not using birth control or using only oral contraception as birth control; Subjects who were breastfeeding; Subjects who had already participated in CT 19.4.209B, or in another trial with Org 25969; Subjects who had participated in another clinical trial, not preapproved by Organon, within 6 months of entering into CT 19.4.209B.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>